KAMPALA, Uganda — Dei BioPharma, a global biotechnology company focused on affordable, next-generation medicines, today announced the development of a CRISPR-based gene therapy platform for sickle cell disease (SCD) invented by Matthias Magoola, Founder...
Durban City, South Africa – Dei BioPharma Founder Dr. Matthias Magoola, has announced at a meeting of the African Center for Disease Control (CDC), that the Ugandan firm has now...
KAMPALA – The Dei BioPharma manufacturing facility in Matugga, Wakiso District, has officially commenced production of pharmaceutical products, marking a major milestone in Uganda’s drive to develop its local biotechnology...
Introduction: The Urgent Need for Cancer Treatment in Africa Cancer is rapidly becoming one of Africa’s most pressing health challenges. In Uganda alone, thousands of new cancer cases are reported...
The U.S. Food and Drug Administration (FDA) has accepted an application from Uganda’s Dei BioPharma for the review of its Abbreviated New Drug Application (ANDA) for liraglutide, a multibillion-dollar treatment...
Learn how Contract Development and Manufacturing Organizations(CDMOs) like Dei Biopharma are transforming pharmaceutical manufacturing in Uganda and across Africa.
